Pipeline
Programs in discovery and preclinical development
Four internal programs and one contract-funded program, as the company described them in 2011.
Preclinical
SND-121 · Neuropathic pain
Oral small molecule; positive results in rat models of neuropathic pain, with a mechanism distinct from opioids, NSAIDs, gabapentin and pregabalin. Prodrugs under study for solubility and GI permeability.
Discovery
SND-159 · Tuberculosis
Active against the TB bacterium, including an MDR-TB strain, in culture; also reduced viability of latent TB strains. Investigated alone and in combination with current TB drugs.
Discovery
SND-226 · Toxoplasmosis
Sub-100 nM inhibitory activity against T. gondii in laboratory studies; further work aimed at confirming results in animal models.
Early discovery
FXS program · Fragile X Syndrome
Early-stage discovery aimed at neurological disorders, including Fragile X Syndrome, the most common known cause of autism and autistic-like behaviours.
Preclinical development
Biowarfare pathogens · DTRA-TMT contract
A three-year contract, up to $8.2 million, for discovery and preclinical development of medical treatments against biowarfare pathogens, with UMDNJ-NJMS.
Lead program
SND-121 for neuropathic pain
The company’s preclinical lead compound has shown safety and efficacy when administered orally in rodent models of neuropathic pain, with a mechanism of action the company describes as distinct from opioid narcotics, NSAIDs, gabapentin and pregabalin.
Further preclinical work is underway on prodrugs of SND-121 with improved water solubility and GI permeability for better systemic uptake when taken orally.
Where the record stops
These are preclinical and discovery-stage programs as described on the company’s own site. No clinical trial results, regulatory filings or approvals are claimed here.
Working with Snowdon
Partnering, licensing and scientific enquiries
The company published one inbox for enquiries and one for employment. Both are reproduced as they stood.